sym015 (anti-met) in patients with advanced solid tumor malignancies

Conditions: Oncology; MET Gene Amplification; NSCLC; MET Gene Mutation; Non Small Cell Lung Cancer

Summary: this is the first study to test sym015 in humans. the primary purpose of this study is to see if sym015 is safe and effective for patients with advanced solid tumor malignancies without available therapeutic options.

in the first part of the study (part 1, dose-escalation), sym015 was evaluated for safety and tolerability. additionally, the recommended phase 2 dose (rp2d) was to be determined. sym015 was given at different dose levels on an every second week (q2w) dosing schedule. each patient was given one single weight based dose level. in the second part of the study (part 2, dose-expansion), dosing was to be at the rp2d on a q2w dosing schedule. three cohorts were included: * basket cohort: patients with kras wild-type (wt) advanced solid tumor malignancies with met-amplification and without therapeutic options. patients must have no prior therapy with met-targeting agents, except a subset of patients having received prior therapy with a met-targeting tyrosine kinase inhibitor (tki). as of december 2018, accrual to this cohort was suspended. * non-small cell lung carcinoma (nsclc) met-amplified cohort: patients with advanced nsclc with met-amplification, and without available therapeutic options. patients may have received prior therapy with met-targeting and/or epidermal growth factor receptor (egfr)-targeting agents. * nsclc with met exon 14 skipping alteration (metex14del) cohort: patients with advanced nsclc metex14del, and without therapeutic options. tumors need not be met-amplified, and patients may have received prior therapy with met-targeting and/or egfr-targeting agents.

Eligibility criteria:
inclusion criteria: * eastern cooperative oncology group (ecog) performance status (ps) of 0 or 1. * life expectancy \>3 months assessed during screening. * documented (histologically- or cytologically-proven) solid tumor malignancy that is locally advanced or metastatic, and that is refractory to standard therapy or for which no standard therapy is available or accessible. * if female and of childbearing potential: a negative pregnancy test. * male or female: either not of childbearing potential or agreeing to use a medically effective method of contraception as per institutional standards during the trial and for 4 months after the last dose of trial drug. * part 1 only: tumor documented to be kras wt by local assessment. * part 2 only: * measurable disease according to recist v1.1 that has been confirmed by computed tomography (ct) or magnetic resonance imaging (mri) within 4 weeks prior to cycle 1/day 1 (c1/d1). * basket cohort only: * tumor documented to be kras wt by local assessment according to institutional standards. if kras wt is not previously documented and if archival tissue is not available for pretrial assessment, patient must be willing to undergo a tumor biopsy to confirm eligibility. * confirmed met-amplification by local assessment. * no prior therapy with met-targeting agents (except a subset of patients having received prior therapy with a met-targeting tki). * willingness to undergo a pre- and post-dosing biopsy (maximum of 2 biopsies) from primary or metastatic tumor site(s) considered safely accessible for biopsy * nsclc met-amplified cohort only: * documented nsclc meeting disease criteria as defined per protocol. * documented met-amplification. * may have received prior therapy with met-targeting and/or egfr-targeting agents (antibodies or tkis). * willingness to undergo a pre-dosing biopsy (mandatory unless a recent tumor biopsy is available), and potentially a biopsy at the end of cycle 2 (eoc2) (optional), from a primary or metastatic tumor site considered safely accessible for biopsy. * nsclc metex14del cohort only: * documented nsclc meeting disease criteria as defined per protocol. * documented metex14del (tumors need not be met-amplified). * may have received prior therapy with met-targeting and/or egfr-targeting agents (antibodies or tkis). * willingness to undergo a pre-dosing biopsy (mandatory unless a recent tumor biopsy is available), and potentially a biopsy at the eoc2 (optional), from a primary or metastatic tumor site considered safely accessible for biopsy. exclusion criteria: * any antineoplastic agent for the primary malignancy (standard or investigational) without delayed toxicity within 4 weeks or 5 plasma half-lives, whichever is shortest, prior to c1/d1, except nitrosoureas and mitomycin c within 6 weeks prior to c1/d1. * immunosuppressive or systemic hormonal therapy within 2 weeks prior to c1/d1, with exceptions. * use of hematopoietic growth factors within 2 weeks prior to c1/d1. * active second malignancy or history of another malignancy within the last 3 years, with exceptions. * central nervous system (cns) malignancy including primary malignancies of the cns and known, untreated cns or leptomeningeal metastases, or spinal cord compression; patients with any of these not controlled by prior surgery or radiotherapy, or symptoms suggesting cns involvement for which treatment is required. * inadequate recovery from an acute toxicity associated with any prior antineoplastic therapy. * major surgical procedure within 4 weeks prior to c1/d1 or inadequate recovery from any prior surgical procedure. * active thrombosis, or a history of deep vein thrombosis or pulmonary embolism, within 1 month prior to c1/d1, unless adequately treated and stable. * active uncontrolled bleeding or a known bleeding diathesis. * significant cardiovascular disease or condition. * abnormal hematologic, renal or hepatic function. * part 2 only: * radiotherapy against target lesions within 4 weeks prior to c1/d1, unless there is documented progression of the lesion following the radiotherapy. * basket cohort only: * prior therapy with met-inhibiting agents (exceptions will be a subset of patients that will be entered to the basket cohort after having received prior therapy with a met-targeting tki). * prior therapy with antibody to hepatocyte growth factor (hgf). * basket cohort and nsclc met-amplified cohort only: * tumor status demonstrating met-polysomy in the absence of met-amplification, as specified per protocol. patients in the nsclc metex14del cohort with polysomy are eligible.

Keywords: advanced solid tumor malignancies met gene amplification met amplification wild-type nsclc metex14del non-small cell lung carcinoma